SEC Form SC 13G/A filed by ChromaDex Corporation (Amendment)

6/24/22 9:28:54 PM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $CDXC alert in real time by email

SC 13G/A 1 20220622_CDXC_13GA.txt 20220625 13G/A REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ChromaDex Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 171077407 (CUSIP Number) June 22, 2022. (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G CUSIP No. 171077407 1 Names of Reporting Persons Yong Rong (HK) Asset Management Limited 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [ ] 3 Sec Use Only 4 Citizenship or Place of Organization Hong Kong Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 3,346,153 (1) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 3,346,153 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 3,346,153 (1) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) -0- 11 Percent of class represented by amount in row (9) 4.90% (2) 12 Type of Reporting Person (See Instructions) CO (1) Represents part of the sum of 3,846,153 shares of common stocks of the Issuer issuable to EverFund pursuant to the Securities Purchase Agreement entered into between the Issuer and EverFund on February 20, 2021 (as reported in the Issuer's Current Report on Form 8-K as filed by the Issuer with the SEC on February 22, 2021). (2) Based on 68,334,586 shares of the Issuer's common stock outstanding as of June 22, 2022. SCHEDULE 13G CUSIP No. 171077407 1 Names of Reporting Persons EverFund 2 Check the appropriate box if a member of a Group (see instructions) (a) [ ] (b) [ ] 3 Sec Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 3,346,153 (1) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 3,346,153 (1) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 3,346,153 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) -0- 11 Percent of class represented by amount in row (9) 4.90% (2) 12 Type of Reporting Person (See Instructions) CO (1) Represents part of the sum of 3,846,153 shares of common stocks of the Issuer issuable to EverFund pursuant to the Securities Purchase Agreement entered into between the Issuer and EverFund on February 20, 2021 (as reported in the Issuer's Current Report on Form 8-K as filed by the Issuer with the SEC on February 22, 2021). (2) Based on 68,334,586 shares of the Issuer's common stock outstanding as of June 22, 2022. Item 1. Issuer (a) Name of Issuer: ChromaDex Corporation (the "Issuer") (b) Address of Issuer's Principal Executive Offices: 10900 Wilshire Blvd., Suite 600 Los Angeles, California 90024 Item 2. Filing Person (a) Name of Person Filing: i) Yong Rong (HK) Asset Management Limited; ii) EverFund; and (b) Address of Principal Business Office or, if None, Residence: i) Yong Rong (HK) Asset Management Limited: Suite 3008, 30/F, Two Exchange Square, 8 Connaught Place, Central, Hong Kong; ii) EverFund: PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands; and (c) Citizenship: i) Yong Rong (HK) Asset Management Limited, a Hong Kong private company limited by shares; ii) EverFund, a Cayman Islands company with limited liability; (d) Title and Class of Securities: Common stock, $0.001 par value per share (e) CUSIP No.: 171077407 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) _ Broker or dealer registered under Section 15 of the Act; (b) _ Bank as defined in Section 3(a)(6) of the Act; (c) _ Insurance company as defined in Section 3(a)(19) of the Act; (d) _ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) _ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) _ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) _ A parent holding company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G); (h) _ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) _ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) _ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); (k) _ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership (a) and (b) Amount Beneficially Owned and Percent of Class: i) EverFund directly owns 3,346,153 shares of common stocks of the Issuer, which represents approximately 4.90% of the outstanding shares of common stock of the Issuer. ii) Yong Rong (HK) Asset Management Limited (the "Investment Manager") is the sole investment manager of EverFund, as such, the Investment Manager collectively may be deemed to beneficially own 3,346,153 shares of common stock and underlying swaps of the Issuer, which represents approximately 4.90% of the outstanding shares of common stock of the Issuer. (c) Number of shares as to which such person has: Number of Shares of Common Stock Reporting Person Yong Rong (HK) Asset Management Limited (i) 3,346,153 (iii) 3,346,153 EverFund (i) 3,346,153 (iii) 3,346,153 (i) Sole power to vote or direct the vote (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of (iv) Shared power to dispose or to direct the disposition of Item 5. Ownership of Five Percent or Less of a Class. Not applicable Item 6. Ownership of more than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not applicable Item 8. Identification and classification of members of the group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: June 22, 2022. YONG RONG (HK) ASSET MANAGEMENT LIMITED By: /s/ Huang Yong Name: Huang Yong Title: Director of the Investment Manager EVERFUND By: /s/ Cai Xiaoxiao Name: Cai Xiaoxiao Title: Fund Director EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate. Dated: June 22, 2022. YONG RONG (HK) ASSET MANAGEMENT LIMITED By: /s/ Huang Yong Name: Huang Yong Title: Director of the Investment Manager EVERFUND By: /s/ Cai Xiaoxiao Name: Cai Xiaoxiao Title: Fund Director

Get the next $CDXC alert in real time by email

Date	Price Target	Rating	Analyst
8/16/2022		Outperform → Perform	Oppenheimer
8/11/2022	$6.00 → $2.40	Buy → Neutral	B. Riley Securities
3/10/2022	$16.00 → $8.00	Buy	B. Riley Securities
3/8/2022	$7.00	Buy	ROTH Capital
8/4/2021	$11.00 → $12.00	Buy	HC Wainwright & Co.

SEC Form SC 13G/A filed by ChromaDex Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $CDXC

$CDXC SEC Filings

ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by ChromaDex Corporation

$CDXC Press Releases

Fastest customizable press release news feed in the world

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

$CDXC Leadership Updates

Live Leadership Updates

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex to Join Russell 2000® Index

$CDXC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

SEC Form 4 filed by Chief Executive Officer Fried Robert N

SEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis

$CDXC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

Chief Financial Officer Pamir Ozan bought $21,397 worth of shares (2,907 units at $7.36) (SEC Form 4)

Gerber Brianna bought $7,050 worth of shares (5,000 units at $1.41), increasing direct ownership by 22% to 27,436 units (SEC Form 4)

$CDXC Financials

Live finance-specific insights

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

$CDXC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

SEC Form SC 13D/A filed by ChromaDex Corporation (Amendment)

$CDXC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ChromaDex downgraded by Oppenheimer

ChromaDex downgraded by B. Riley Securities with a new price target

B. Riley Securities reiterated coverage on ChromaDex with a new price target

Recent Analyst Ratings for
$CDXC

$CDXC
SEC Filings

$CDXC
Press Releases

$CDXC
Leadership Updates

$CDXC
Insider Trading

$CDXC
Insider Purchases

$CDXC
Financials

$CDXC
Large Ownership Changes

$CDXC
Analyst Ratings